What is Aitia?
Aitia aims to accelerate the discovery and development of life-saving therapeutics by revealing hidden biological mechanisms of disease. This is achieved through the application of causal AI and the creation of Gemini Digital Twins, which are constructed from comprehensive multi-omic patient data.
The company employs advanced AI approaches designed to disrupt traditional drug discovery methods, particularly in oncology and neurodegenerative diseases. By building these detailed digital models of human diseases, Aitia seeks to unlock the potential for identifying novel, first-in-kind therapeutic programs and make a significant impact on patient lives through strategic partnerships.
Features
- Causal AI Engine: Utilizes causal AI to uncover underlying biological mechanisms of diseases.
- Gemini Digital Twins: Creates digital representations of human diseases from multi-omic patient data.
- AI-Driven Drug Discovery: Applies AI to identify and develop novel therapeutic programs.
- Focus on Oncology & Neurodegenerative Diseases: Specializes pipeline development in these critical therapeutic areas.
- Strategic Partnerships: Collaborates with industry leaders to advance drug discovery.
Use Cases
- Accelerating drug discovery timelines.
- Identifying novel therapeutic targets.
- Developing first-in-kind treatments for complex diseases like cancer and neurodegenerative disorders.
- Modeling human disease mechanisms with AI.
- Facilitating R&D in oncology.
- Advancing research in neurodegenerative diseases.
